Search results

Search for "prostate cancer" in Full Text gives 27 result(s) in Beilstein Journal of Nanotechnology.

Synthesis of boron nitride nanotubes and their applications

  • Saban Kalay,
  • Zehra Yilmaz,
  • Ozlem Sen,
  • Melis Emanet,
  • Emine Kazanc and
  • Mustafa Çulha

Beilstein J. Nanotechnol. 2015, 6, 84–102, doi:10.3762/bjnano.6.9

Graphical Abstract
  • composites in the presence and absence of a magnetic field [84]. The BNNT–NaGdF4:Eu composites simultaneously show fluorescent and magnetic properties. Thus, imaging and targeting of the composites can be more easily achieved. Human LNCaP prostate cancer cells were treated with the BNNT–NaGdF4:Eu composites
  • in the presence and absence of a magnetic field and higher cell-associated uptake was found in the presence of a magnetic field. Then, the composites were loaded with doxorubicin (dox) to investigate the viability of LNCaP prostate cancer cells in the magnetic field. It was found that dox-loaded BNNT
  • pH dependent and both negatively and positively charged structures had the same dox loading capacity. The BNNT–MS–NH2 had higher uptake potential in LNCaP prostate cancer cells due to its charge. Thus, it had a higher toxicity towards LNCaP prostate cancer cells. It was concluded that the prepared
PDF
Album
Review
Published 08 Jan 2015

Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer

  • Amanee D Salaam,
  • Patrick Hwang,
  • Roberus McIntosh,
  • Hadiyah N Green,
  • Ho-Wook Jun and
  • Derrick Dean

Beilstein J. Nanotechnol. 2014, 5, 937–945, doi:10.3762/bjnano.5.107

Graphical Abstract
  • delivery system for bone metastatic prostate cancer was developed, characterized, and evaluated in vitro. NDs were conjugated with the Asp–Gly–Glu–Ala (DGEA) peptide to target α2β1 integrins over-expressed in prostate cancers during metastasis. To facilitate drug delivery, DOX was adsorbed to the surface
  • ; doxorubicin; nanodiamond; prostate cancer; targeted drug delivery; Introduction Prostate cancer is the most frequently diagnosed malignancy in men [1]. Typically the disease is slow growing, but in some cases it progresses to an aggressively metastatic state. When prostate cancer becomes metastatic, the
  • current standard of care is chemotherapy, which involves the use of toxic anticancer drugs, like doxorubicin (DOX), to treat cancers by inducing apoptosis. DOX has had high success rates with treating prostate cancer [2]. However, it can cause major side effects such as hair loss, nausea [2][3], and
PDF
Album
Full Research Paper
Published 01 Jul 2014
Other Beilstein-Institut Open Science Activities